-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VVD-130850 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VVD-130850 in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VVD-130850 in Non-Hodgkin Lymphoma Drug Details: VVD-130850 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VVD-130850 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VVD-130850 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VVD-130850 in Solid Tumor Drug Details: VVD-130850 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VVD-130850 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VVD-130850 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VVD-130850 in Non-Small Cell Lung Cancer Drug Details: VVD-130850...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BAY-3605349 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BAY-3605349 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BAY-3605349 in Solid Tumor Drug Details: BAY-3605349 is under development for...
-
Product Insights
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region. The Nuclear Factor Erythroid 2 Related Factor 2 - Drugs...
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends for August 2021 in Pharmaceuticals
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for August 2021 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in August 2021. The report portrays detailed comparative data on the number of deals and their value in the last...